{"id":"advagraf-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL3400969","moleculeType":"Small molecule","molecularWeight":"413.48"},"_fixedAt":"2026-03-30T16:01:32.954014","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus binds to the immunophilin FKBP12 and inhibits calcineurin, a phosphatase required for T-cell receptor signaling and IL-2 production. The extended-release QD formulation allows for once-daily dosing compared to twice-daily immediate-release tacrolimus, improving medication adherence in transplant recipients while maintaining immunosuppressive efficacy.","oneSentence":"Advagraf QD is a once-daily extended-release formulation of tacrolimus that suppresses T-cell activation by inhibiting calcineurin phosphatase.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:57.989Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in adult kidney transplant recipients"},{"name":"Prevention of organ rejection in adult liver transplant recipients"}]},"_fixedFields":["pubmed(7)"],"trialDetails":[{"nctId":"NCT03256864","phase":"PHASE4","title":"Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2016-01","conditions":"Liver Transplantation","enrollment":10},{"nctId":"NCT03216447","phase":"PHASE4","title":"A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2017-11-23","conditions":"Liver Transplantation","enrollment":150},{"nctId":"NCT02882113","phase":"PHASE4","title":"Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-07","conditions":"Liver Dysfunction","enrollment":60},{"nctId":"NCT02805842","phase":"PHASE3","title":"Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2016-08","conditions":"Medication Adherence","enrollment":60},{"nctId":"NCT01680952","phase":"PHASE4","title":"Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-09","conditions":"Kidney Transplant Patients","enrollment":158},{"nctId":"NCT01092806","phase":"PHASE4","title":"Insulin Secretion and Advagraf","status":"COMPLETED","sponsor":"University of Oslo School of Pharmacy","startDate":"2009-10","conditions":"Post Transplant Diabetes Mellitus","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advagraf"],"phase":"phase_3","status":"active","brandName":"Advagraf QD","genericName":"Advagraf QD","companyName":"Rabin Medical Center","companyId":"rabin-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Advagraf QD is a once-daily extended-release formulation of tacrolimus that suppresses T-cell activation by inhibiting calcineurin phosphatase. Used for Prevention of organ rejection in adult kidney transplant recipients, Prevention of organ rejection in adult liver transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}